Generic Name and Formulations:
Gadopentetate dimeglumine 469.01mg/mL; soln for IV inj; preservative-free.
Indications for MAGNEVIST:
For use in MRI to facilitate the visualization of lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues; in the head and neck; and in the body (excluding the heart).
Adults and Children:
<2yrs: not established. ≥2yrs: 0.1mmol/kg (0.2mL/kg) IV at a rate of 10mL/15secs, followed by a 5mL normal saline flush (to ensure complete injection). Patients >286 lbs: dose not established.
Chronic, severe kidney disease (GFR<30mL/min/1.73m2). Acute kidney injury.
Increased risk of nephrogenic systemic fibrosis among patients with renal impairment (eg, >60yrs, diabetes mellitus, chronic hypertension). Screen for renal dysfunction. Acute renal failure possible in patients with renal insufficiency within 48hrs of inj; use lowest possible dose and evaluate renal function. Do not exceed recommended dose; allow sufficient period of time for elimination prior to re-administration. History of asthma and/or allergy disorders. Have resuscitative equipment available. Discontinue if hypersensitivity reactions occur. Interpreting Magnevist MRI scans without a companion non-contrast MRI scan. Pregnancy (Cat.C). Nursing mothers.
Paramagnetic contrast agent (Gadolinium-based).
Headache, nausea, inj site coldness/localized coldness, dizziness; rare: inj site reactions, hypersensitivity reactions.
Single-dose vials (5mL, 10mL, 15mL, 20mL)—20; Pre-filled syringes (10mL, 15mL, 20mL)—5
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|